Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes

Bibliography

• Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with Type 1 and Type 2 diabetes – a meta-analysis. Osteoporos Int 2007;18(4):427-44
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91(9):3349-54
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, et al. The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92(4):1305-10
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (GSK). Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia® (rosiglitazone maleate) tablets for Type 2 diabetes mellitus (Letter to Health Care Providers). Available from: URL: www.fda.gov/MedWatch/safety/2007/Avandia_GSK_Ltr.pdf [last accessed February 2007]
   Google Scholar
• Melton LJ III, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999;9(1):29-37
   PubMed Web of Science ®Google Scholar
• Takeda. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for Type 2 diabetes mellitus. (Letter to Health Care Providers). Available from: URL: www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf [last accessed March 2007]
   Google Scholar
• Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decreases bone mineral density in Type 2 diabetic men. Diabetes Care 2007;30(6):1574-6
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92(9):3523-30
   PubMed Web of Science ®Google Scholar
• Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145(1):401-6
   PubMed Web of Science ®Google Scholar
• Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146(3):1226-35
   PubMed Web of Science ®Google Scholar
• Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183(1):203-16
   PubMed Web of Science ®Google Scholar
• Jennermann C, Triantafillou J, Cowan D, et al. Effects of thiazolidinediones on bone turnover in the rat. J Bone Miner Res 1995;10:S241 (Abstract S361)
   Google Scholar
• Syversen U, Stunes A, Gustafsson B, et al. The PPAR gamma agonist fenofibrate prevents bone loss, while the PPAR alpha agonist pioglitazone exaggerates bone loss in ovarectomized rats. J Bone Miner Res 2006;21(Suppl 1):S216 (Abstract SU042)
   Google Scholar
• Semple RK, Chatterjee VK, thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50(5):1087-94
   PubMed Web of Science ®Google Scholar
• Hong JH, Hwang ES, McManus MT, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005;309(5737):1074-8.
   PubMed Web of Science ®Google Scholar
• Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50(5):1087-94.
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999;74:357-71
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Suva LJ. Resolving the two “bony” faces of PPAR-gamma. PPAR Res 2006;2006:27489
   PubMedGoogle Scholar
• Akune T, Ohba S, Kamekura S, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Investig 2004;113(6):846-55
   PubMed Web of Science ®Google Scholar
• Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102(9):3324-9
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Ackert-Bicknell CL, Adamo ML, et al. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 2004;35(5):1046-58
   PubMed Web of Science ®Google Scholar
• Ogawa S, Urano T, Hosoi T, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 1999;260(1):122-6
   PubMed Web of Science ®Google Scholar
• Kiel DP, Ferrari S, Cupples LA, et al. Polymorphisms in the PPARgamma gene influence bone density in humans. J Bone Miner Res 2005;209(Suppl 1):S234-5 (Abstract)
   Google Scholar
• Hsu Y, Zhang Y, Xu X, et al. Genetic variation in ALOX15, BMP2, PPARr and IGF1 gene is associated with BMD. J Bone Miner Res 2004;19(Suppl 1):S386 (Abstract)
   PubMed Web of Science ®Google Scholar
• Klein RF, Allard J, Avnur Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004;303(5655):229-32
   PubMed Web of Science ®Google Scholar
• Tornvig L, Mosekilde LI, Justesen J, et al. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 2001;69(1):46-50
   PubMed Web of Science ®Google Scholar
• Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006;38(1):74-84
   PubMed Web of Science ®Google Scholar
• Li M, Pan LC, Simmons HA, et al. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 2006;39(4):796-806
   PubMed Web of Science ®Google Scholar
• Okazaki R, Toriumi M, Fukumoto S, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999;140:5060-5
   PubMed Web of Science ®Google Scholar
• Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004;75(4):329-37
   PubMed Web of Science ®Google Scholar
• Lazarenko OP, Rzonca SO, Hogue WR, et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007;148(6):2669-80
   PubMed Web of Science ®Google Scholar
• Cao JJ, Wronski TJ, Iwaniec U, et al. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 2005;20(9):1659-68
   PubMed Web of Science ®Google Scholar
• Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60(6):1604-8
   PubMed Web of Science ®Google Scholar
• Mu YM, Yanase T, Nishi Y, et al. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 2000;271(3):710-13
   PubMed Web of Science ®Google Scholar
• Chappard D, Moquereau M, Mercier P, et al. Ex vivo bone mineral density of the wrist: influence of medullar fat. Bone 2004;34(6):1023-8
   PubMed Web of Science ®Google Scholar
• Justesen J, Mosekilde L, Holmes M, et al. Mice deficient in 11beta-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology 2004;145(4):1916-25
   PubMed Web of Science ®Google Scholar
• Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? The study of osteoporotic fractures research group. Ann Intern Med 1991;115(11):837-42
   PubMed Web of Science ®Google Scholar
• Sanders KM, Seeman E, Ugoni AM, et al. Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 1999;10(3):240-7
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13(10):777-87
   PubMed Web of Science ®Google Scholar
• Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 2000;15(6):1006-13
   PubMed Web of Science ®Google Scholar
• Keegan TH, Schwartz AV, Bauer DC, et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in Type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004;27(7):1547-53
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102(8):1627-33
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, DE Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-22
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-68.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86(1):32-8
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48(7):1292-9
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
   PubMed Web of Science ®Google Scholar
• Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001;24(7):1192-7
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007;30(4):835-41
   PubMed Web of Science ®Google Scholar
• Volpato S, Leveille SG, Blaum C, et al. Risk factors for falls in older disabled women with diabetes: the women's health and aging study. J Gerontol A Biol Sci Med Sci 2005;60(12):1539-45
   PubMed Web of Science ®Google Scholar